MetaCap

Damora Therapeutics (DMRA) vs Sarepta Therapeutics (SRPT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Damora Therapeutics (DMRA) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 38.5% versus a loss of 24.6%. Over five years, DMRA leads with a -68.8% price change compared with -83.3% for SRPT. Damora Therapeutics is the larger company by market cap ($1.44 billion vs $1.43 billion), about 1.0 times the size.

On valuation, Damora Therapeutics trades at a lower trailing P/E (13.6x vs 666.5x for Sarepta Therapeutics).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DMRA+38.46%SRPT-24.65%
+110%+39%-31%
Nov 21, 20251 yearNov 20, 2026
DMRA-69.04%SRPT-83.34%
+111%+2%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DMRA versus SRPT key metrics
MetricDMRASRPT
Share price$23.22$13.33
Market cap$1.44B$1.43B
1-day change-4.44%-5.93%
YTD return+0.91%-38.06%
1-year return+38.46%-24.65%
5-year return-68.83%-83.26%
P/E ratio (TTM)13.58666.50
Forward P/E—8.87
EPS (TTM)$1.71$0.02
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.20B
Revenue growth (YoY)—+15.58%
Net income (latest FY)$-209.84M$-713.41M
Gross margin—98.84%
Operating margin—-31.83%
Net margin—-32.45%
52-week high$38.33$24.68
52-week low$15.76$13.25
Distance from 52-week high-39.41%-45.99%
Analyst consensusstrong_buyhold
Avg. price target upside+101.46%+63.32%
Average volume584.28K2.70M
Shares outstanding61.90M107.24M
Employees7835
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DMRA has outperformed SRPT by 63.1 percentage points over the past year.
  • Sarepta Therapeutics trades at a higher earnings multiple (666.5x vs 13.6x trailing P/E).

About Damora Therapeutics

DMRA stock →

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Sarepta Therapeutics

SRPT stock →

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.

Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees

DMRA vs SRPT FAQ

Which is bigger, Damora Therapeutics or Sarepta Therapeutics?

Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.44B compared with $1.43B for Sarepta Therapeutics (SRPT).

Which stock has performed better over the past year, DMRA or SRPT?

DMRA returned +38.46% over the past 12 months, compared with -24.65% for SRPT (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, DMRA or SRPT?

DMRA has the lower trailing P/E at 13.6, versus 666.5 for SRPT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Damora Therapeutics and Sarepta Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons